Trial · NCT02739217
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Description and number of abnormal laboratory values and adverse events that are related to treatment. | Primary on 24 weeks; Final on all data (including Extension Period) | |
| Secondary | Change from baseline in metabolic syndrome parameters over time. | 24 weeks and end of Extension Period | Change from baseline in fasting plasma glucose over time. Change from baseline in fasting plasma insulin over time. Change from baseline in glycated hemoglobin (HbA1c) over time. Change from baseline in Homeostasis Model Assessment for steady state beta cell function (HOMA-B) and insulin sensitivity (HOMA-S) over time. |
| Secondary | Change from baseline in biomarkers in blood and urine over time | 24 weeks and end of Extension Phase | Percentage of reduction and/or increase of level of biomarkers |
| Secondary | Change from baseline in cardiac function parameter: NT-proBNP | 24 weeks and end of Extension Phase | |
| Secondary | Change from baseline of antidiabetic treatment | 24 weeks and end of Extension Phase | Dosing change, new medication added or treatment discontinuation |
| Other | Changes from baseline in histological appearances in fat biopsies | 24 weeks and end of Extension Phase | Measuring the degree of fibrosis |
| Other | Changes from baseline in global metabolome and microdialysate fractions | 24 weeks and end of Extension Phase | |
| Other | Change from baseline in the liver stiffness | 24 weeks and end of Extension Phase | Measured in kilopascal (kPa) correlated to fibrosis by using a FibroScan |
| Other | Change from baseline in fat content and fibrosis burden in liver MRI | 24 weeks and end of Extension Phase | |
| Other | Change from baseline in left ventricular ejection fraction in cardiac MRI | 24 weeks and end of Extension Phase | |
| Other | Change from baseline in blood glucose as measured by weekly 4 point profile | 24 weeks and end of Extension Phase | |
| Other | Change from baseline in hyperinsulinaemic-euglycaemic clamp measurements. | 24 weeks and end of Extension Phase |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02739217/registered